MedTrace Logo

Pre-malignant States to Hematologic Malignancies in Firefighters

NCT06870760 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2026-04-16

No results posted yet for this study

Summary

The purpose of the study is to evaluate if firefighter exposure to hazardous compounds will increase the incidence of premalignant hematological states which subsequently increases the risk of the development of hematologic malignancies, and potentially other pathophysiological consequences.

Conditions

  • Clonal Hematopoiesis of Indeterminate Potential
  • Monoclonal Gammopathy
  • Non Hodgkin Lymphoma
  • Leukemia
  • Multiple Myeloma
  • Plasma Cell Disorder

Interventions

OTHER

Monoclonal Gammopathy

Whole blood will be collected at the Baseline visit to evaluate for monoclonal gammopathy through SPEP, immunofixation, and free light chains.

OTHER

Complete Blood Count with differential (CBC w/ diff)

Whole blood will be collected at the Baseline visit for CBC with differential which may inform a diagnosis of a plasma cell disorder or other hematological disorder.

OTHER

Clonal hematopoiesis (CHIP)

Whole blood will be collected at the Baseline visit to be evaluated using next generation sequencing (NGS) detection of CHIP. Deep NGS to identify mutations associated with myeloid neoplasms and CHIP will be performed using an error-correcting next generation sequencing multi-gene panel targeting genes most frequently mutated in CHIP.

Sponsors & Collaborators

  • Atrium Health Levine Cancer Institute

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Larry Druhan, PhD · Wake Forest University Health Sciences

Eligibility

Min Age
40 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-04-30
Completion
2027-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06870760 on ClinicalTrials.gov